Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

N. T	c		. • .
Name	OŤ.	en	titv

#### FRONTIER RESOURCES LIMITED

ABN

96 095 684 389

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 1. Fully Paid Ordinary
- 2. Unlisted Options
- 3. Fully Paid Ordinary
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 371,875,000
   185,937,500
- 3. 5.625.000
- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1. Fully Paid Ordinary
- 2. Unlisted Options exercisable at \$0.029 expiring 1 June 2020
- 3. Fully Paid Ordinary

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	<ol> <li>\$0.016 per share</li> <li>Free attaching options</li> <li>N/A</li> </ol>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol> <li>8 2: Issue of subscription shares and options to Forise and ACH as approved at the Company's General Meeting held on 15 May 2018</li> <li>Conversion of working capital loan to shares at \$0.016 per share.</li> </ol>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2017
6с	Number of *securities issued without security holder approval under rule 7.1	3. 5,625,000
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	1. 371,875,000 2. 185,937,500 Approved at the Gener May 2018.	ral Meeting held on 15
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	<sup>+</sup> Issue dates	19 June 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.		
8	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	Number 489,101,938	+Class Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

	Г	Normalia a m	+C1
9	Number and <sup>+</sup> class of all <sup>+</sup> securities	Number 187,500,000	+Class Unlisted Options
,	not quoted on ASX (including the	187,300,000	exercisable at \$0.029
	+securities in section 2 if		expiring 1 June 2020
	applicable)		1 0
	_		
10	Dividend policy (in the case of a trust, distribution policy) on the	N/A	
	increased capital (interests)		
Part 2	? - Pro rata issue		
11	Is security holder approval required?	N/A	
11	is security notice approval required.	14/11	
12	Is the issue renounceable or non-renounceable?	N/A	
	renounceable:		
13	Ratio in which the +securities will be	N/A	
	offered		
14	<sup>+</sup> Class of <sup>+</sup> securities to which the	N/A	
14	offer relates	IV/A	
15	+Record date to determine	N/A	
	entitlements		
16	Will holdings on different registers	N/A	
	(or subregisters) be aggregated for		
	calculating entitlements?		
17	Policy for deciding entitlements in	N/A	
	relation to fractions		
18	Names of countries in which the	N/A	
	entity has security holders who will		
	not be sent new offer documents		
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
10	Closing data for	NT/A	
19	Closing date for receipt of acceptances or renunciations	N/A	
	r		
20	Names of any underwriters	N/A	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of \*securities (tick one)

(a) +Securities described in Part 1

(b) All other \*securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the +securities are +equity securities, the names of the 20 largest holders of the
	additional +securities, and the number and percentage of additional +securities held by
	those holders

If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories

1 - 1,000 1,001 - 5,000

5,001 - 10,000

10,001 - 100,000 100,001 and over

A copy of any trust deed for the additional \*securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entities	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another +security, clearly identify that other +security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: (lodged electronically) Date: 19 June 2018

(Company secretary)

Print name: Matthew Foy

== == == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base fig capacity is calculated	ure from which the placement	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	80,400,916	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	22,558,250	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	380,517,772	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	Nil	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid  †ordinary securities cancelled during that  12 month period	Nil	
"A"	483,476,938	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	72,521,540
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	5,625,000
<ul> <li>Under an exception in rule 7.2</li> </ul>	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	5,625,000
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-
"A" x 0.15	72,521,540
Note: number must be same as shown in Step 2	
Subtract "C"	5,625,000
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	66,896,540
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1	483,476,938	
Step 2: Calculate 10% of "A"  "D"	0.10  Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	48,347,693	
Step 3: Calculate "E", the amount 7.1A that has already been used  Insert number of *equity securities issued	of placement capacity under rule  Nil	
or agreed to be issued in that 12 month period under rule 7.1A  Notes:  This applies to equity securities – not just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained  It may be useful to set out issues of securities on different dates as separate line items		
"E"	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	48,347,693	
Subtract "E"  Note: number must be same as shown in Step 3	Nil	
<b>Total</b> ["A" x 0.10] – "E"	48,347,693  Note: this is the remaining placement capacity under rule 7.1A	

#### Confirmation under section 708(5)(e) of the Corporations Act (Act)

The Company hereby notifies ASX under section 708A(5)(e) of the Act in compliance with the requirements of section 708A(6) of the Act. The Company also advises that as at the date of this notice:

- 1. The securities were issued without disclosure to investors under Part 6D.2 of the Act;
- 2. the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company;
- 3. the Company has complied with section 674 of the Act; and
- 4. As at the date of this notice, there is no information:
  - a. That has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
  - b. That investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - i. The assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - ii. The rights and liabilities attaching to the shares.

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.